Servier and miRagen Extend Collaboration for the Research, Development and Commercialization of microRNA-targeting Drugs for Cardiovascular Disease

Servier, an independent French research-based pharmaceutical company
with a significant presence in European and emerging markets, and
miRagen Therapeutics, Inc., a biopharmaceutical company developing
innovative microRNA-based therapeutics, announced today that they have
extended their research collaboration by two years to October 2016 to
discover, develop, and commercialize drugs targeting microRNAs for
cardiovascular disease. miRagen and Servier Research will continue
preclinical research and development on multiple cardiovascular programs
targeting microRNAs, including miR-208 and miR-15. Servier will lead the
global clinical development and commercialization of microRNA
therapeutic product candidates developed through the collaboration in
all countries except the U.S. and Japan, where miRagen has retained all

“The two year extension to our research collaboration reflects both the
strength of our relationship with miRagen and our shared commitment to
improve the lives of patients suffering from cardiovascular diseases,”
said Dr. Jean-Paul Vilaine, Director of Servier’s Cardiovascular
Research Unit. “We look forward to continuing our collaboration to
advance microRNA-based therapeutics into clinical development.”

Dr. Emmanuel Canet, Servier’s President of Research and Development,
commented that “Servier’s research efforts in cardiovascular disease are
focused on delivering improved, innovative treatments. Extending our
research collaboration with miRagen to discover novel cardiovascular
miRNA-based therapeutics is a very important component of these efforts.”

“Extending our research collaboration with Servier highlights our
collective dedication to harnessing the power of microRNAs to develop
transformative therapies for patients in need,” said William S.
Marshall, Ph.D., President and Chief Executive Officer of miRagen
Therapeutics, Inc. “We believe that our microRNA therapeutics platform
combined with Servier’s extensive knowledge and commitment to
cardiovascular disease will allow us to deliver breakthrough therapies
that improve human health.”

In October 2011, miRagen entered into a License and Collaboration
Agreement with Servier with the goal of advancing microRNA-based
therapies in cardiovascular disease. The collaboration initially
included two named targets (miR-208 and miR-15/195) and in May 2013
Servier exercised an option to include an additional undisclosed target
to the collaboration. Under the terms of the agreement, miRagen received
an upfront payment in 2011 and an additional payment when Servier
expanded the agreement to cover the additional target in 2013. miRagen
may also receive additional research and development milestone payments,
commercial milestone payments and royalties on the sale of products
developed under the collaboration. Servier will continue to finance the
research, development, regulatory approval, and commercialization costs
of product candidates under the collaboration. miRagen retains all
commercialization rights in the U.S. and Japan, and the option to
co-sponsor any Phase III programs if miRagen elects to seek marketing
approval in the U.S. or Japan for any product developed under the

MicroRNAs have emerged as an important class of small RNAs encoded in
the genome, acting as master regulators of gene expression. Recent
studies have indicated that microRNAs appear to be associated with many
disease processes. Because they are thought to be single molecular
entities that dictate the expression of fundamental regulatory pathways,
microRNAs represent potential drug targets for controlling many biologic
and disease processes.

miRagen Therapeutics, Inc., is a biopharmaceutical company focused on
the discovery and development of innovative microRNA (miRNA)-targeting
therapies in disease areas of high unmet medical need. The Company seeks
to leverage in-house expertise in miRNA biology, oligonucleotide
chemistry, and drug development to evaluate and advance promising
technologies and high-potential product candidates for its own pipeline
and in conjunction with strategic collaborators. For certain
cardiovascular disease programs, miRagen has a collaboration and license
agreement with Servier, an independent French research-based
pharmaceutical company. miRagen retains all rights for the
Servier-partnered programs in the U.S and Japan. For more information,
please visit

Founded in 1954, Servier is an independent French pharmaceutical
research company. Its development is based on the continuous pursuit of
innovation in the therapeutic areas of cardiovascular, metabolic,
neurological, psychiatric and bone and joint diseases as well as
oncology. Servier is established in 140 countries and employs more than
21,000 people worldwide. In 2013, Servier recorded a turnover of 4.2
billion euros of which 27% was reinvested in Research and Development.
91% of Servier drugs are consumed outside France and the Servier Group
contributed 35% to the 2013 French trade surplus in the pharmaceuticals
sector. More information is available at:

1) Mendell, J.T. and Olson, E.N. (2012). MicroRNAs in Stress Signaling
and Human Disease. Cell 148, 1172-1187.

Kecia Carroll,

Source: miRagen